Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018030879) PHARMACEUTICAL COMPOSITION COMPRISING AMODIAQUINE AND ANTI-DIABETES DRUG AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF DIABETES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/030879 International Application No.: PCT/KR2017/008852
Publication Date: 15.02.2018 International Filing Date: 14.08.2017
IPC:
A61K 31/4706 (2006.01) ,A61K 31/155 (2006.01) ,A61K 31/427 (2006.01) ,A61K 45/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4706
4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
155
Amidines (), e.g. guanidine (H2N-C(NH)-NH2), isourea (HNC(OH)NH2), isothiourea (HNC(SH)-NH2)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
427
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants:
주식회사 노브메타파마 NOVMETAPHARMA CO., LTD. [KR/KR]; 서울시 강남구 언주로 727, 13층 (논현동,트리스빌딩) (Trees Building, Nonhyeon-dong) 13th Floor, 727, Eonju-ro, Gangnam-gu, Seoul 06050, KR
포항공과대학교 산학협력단 POSTECH ACADEMY-INDUSTRY FOUNDATION [KR/KR]; 경상북도 포항시 남구 청암로 77 (지곡동) (Jigok-dong) 77, Cheongam-ro, Nam-gu, Pohang-si, Gyeongsangbuk-do 37673, KR
Inventors:
김경태 KIM, Kyong Tai; KR
정회윤 JUNG, Hoe Yune; KR
이헌종 LEE, Heon Jong; KR
Agent:
특허법인 이룸리온 ERUUM & LEEON INTELLECTUAL PROPERTY LAW FIRM; 서울시 서초구 사평대로 108, 3층 (반포동) (Banpo-dong) 3rd Floor, 108, Sapyeong-daero, Seocho-gu, Seoul 06575, KR
Priority Data:
10-2016-010317412.08.2016KR
Title (EN) PHARMACEUTICAL COMPOSITION COMPRISING AMODIAQUINE AND ANTI-DIABETES DRUG AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF DIABETES
(FR) COMPOSITION PHARMACEUTIQUE COMPRENANT COMME PRINCIPES ACTIFS DE L'AMODIAQUINE ET UN MÉDICAMENT ANTI-DIABÈTE, DESTINÉE À LA PRÉVENTION OU LE TRAITEMENT DU DIABÈTE
(KO) 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
Abstract:
(EN) The present invention relates to a pharmaceutical composition comprising (a) an amodiquine compound or a pharmaceutically acceptable salt thereof; and (b) an anti-diabetes drug as effective ingredients for preventing or treating diabetes while suppressing the side effect attributed to the activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ). More particularly, the composition aims to simultaneously prevent or treat type 2 diabetes responsive of the activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ) and at least one selected from the group consisting of obesity, dyslipidemia, cardiovascular diseases, and fatty liver, which are all responsive of the activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ).
(FR) La présente invention concerne une composition pharmaceutique comprenant comme principes actifs (a) un composé amodiquine ou un sel pharmaceutiquement acceptable de ce dernier et (b) un médicament anti-diabète, destinée à prévenir ou traiter le diabète tout en empêchant l'effet indésirable attribué à l'activation du récepteur activé par les proliférateurs de peroxisomes de type gamma (PPAR-γ). Plus particulièrement, la composition vise à prévenir ou traiter simultanément le diabète de type 2, sensible à l'activation du récepteur activé par les proliférateurs de peroxisomes de type gamma (PPAR-γ), et au moins une des pathologies appartenant au groupe constitué par l'obésité, la dyslipidémie, les maladies cardiovasculaires et la stéatose hépatique, toutes sensibles à l'activation du récepteur activé par les proliférateurs de peroxisomes de type gamma (PPAR-γ).
(KO) 본 발명은 (a) 아모디아퀸(amodiaquine) 화합물 또는 이의 약제학적으로 허용 가능한 염; 및 (b) 항당뇨 약물을 유효성분으로 함유하는 PPAR-γ(Peroxisome proliferator-activated receptor-gamma) 활성화에 따른 부작용을 억제하면서, 당뇨병을 예방 또는 치료하기 위한 약학적 조성물에 관한 것으로, 구체적으로, 상기 조성물은 PPAR-γ(Peroxisome proliferator-activated receptor-gamma) 활성화에 반응하는 제2형 당뇨병 및 PPAR-α(Peroxisome proliferator-activated receptor-alpha) 활성화에 반응하는 비만, 이상지질혈증, 심혈관계질환 및 지방간으로 이루어진 군으로부터 선택된 하나 이상을 동시에 예방 또는 치료하기 위한 것이다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)